Chemed Co. (NYSE:CHE) CEO Kevin J. Mcnamara Sells 2,000 Shares

Chemed Co. (NYSE:CHE) CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, November 25th. The shares were sold at an average price of $572.77, for a total transaction of $1,145,540.00. Following the completion of the transaction, the chief executive officer now directly owns 101,735 shares of the company’s stock, valued at $58,270,755.95. The trade was a 1.93 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Chemed Stock Up 0.3 %

CHE opened at $573.57 on Wednesday. Chemed Co. has a twelve month low of $523.33 and a twelve month high of $654.62. The company has a 50-day moving average price of $578.95 and a 200 day moving average price of $564.99. The company has a market cap of $8.63 billion, a PE ratio of 28.98, a price-to-earnings-growth ratio of 2.42 and a beta of 0.46.

Chemed (NYSE:CHE) last released its quarterly earnings results on Tuesday, October 29th. The company reported $5.64 earnings per share for the quarter, missing the consensus estimate of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The company had revenue of $606.18 million for the quarter, compared to analyst estimates of $612.22 million. During the same quarter last year, the company earned $5.32 EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. As a group, sell-side analysts expect that Chemed Co. will post 21.43 earnings per share for the current year.

Chemed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Shareholders of record on Monday, November 18th will be issued a $0.50 dividend. The ex-dividend date is Monday, November 18th. This represents a $2.00 dividend on an annualized basis and a yield of 0.35%. Chemed’s payout ratio is 10.11%.

Institutional Trading of Chemed

A number of hedge funds have recently bought and sold shares of CHE. CreativeOne Wealth LLC acquired a new stake in Chemed in the 1st quarter valued at about $216,000. Lazard Asset Management LLC raised its holdings in Chemed by 565.4% in the 1st quarter. Lazard Asset Management LLC now owns 7,433 shares of the company’s stock valued at $4,771,000 after acquiring an additional 6,316 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Chemed by 105.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 63,733 shares of the company’s stock valued at $40,913,000 after acquiring an additional 32,752 shares during the last quarter. LRI Investments LLC purchased a new stake in shares of Chemed in the 1st quarter valued at approximately $171,000. Finally, Second Line Capital LLC grew its stake in shares of Chemed by 7.1% in the 1st quarter. Second Line Capital LLC now owns 3,648 shares of the company’s stock valued at $2,342,000 after buying an additional 242 shares during the period. Institutional investors and hedge funds own 95.85% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Royal Bank of Canada cut their price objective on shares of Chemed from $697.00 to $633.00 and set an “outperform” rating for the company in a report on Tuesday, November 5th. StockNews.com cut shares of Chemed from a “buy” rating to a “hold” rating in a report on Friday, November 22nd.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.